OpGen Inc (OPGN)

[chillswills37]

How Sandoz chess move affirms OPGN Ares Genetics are crown jewels ripe for takeover.

A takeover, friendly or hostile, to acquire OpGen for the sake of Ares Genetics isn't just likely, it's virtually inevitable in today's highly acquisitive and combative Dx space.

Why? In short, Ares Genetics holds a unique "key" in overcoming AMR and extending the lifetime of disease-fighting, life-saving antibiotics.

Sandoz CEO said so in 6 April 2022 PR: "As the world’s leading provider of generic antibiotics, our goal at Sandoz is to play a key role in overcoming this growing threat. This collaboration (w/OPGN sub Ares Genetics) is a key step towards that goal, allowing us to take the fight directly to AMR by using cutting-edge big data and AI approaches combined with traditional data sets. [i.e., ARESdb + Ares Gen's proprietary digital AI powered DNA testing]."

Keys
1) (ARESdb, ARES data base) OpGen's wholly owned sub Ares Genetics owns the world's largest and most comprehensive data base of genetic antibiotic resistance markers and predictive AMR panels. Continually updated, ARESdb covers an astonishing 30 years of emerging antibiotic resistance to accurately detect AMR.

2) Isolates: The ARESdb contains thousands of whole genome sequenced clinical isolates collected from more than 200 centers globally.

3) ARESdb combines broad resistance profiles with high-quality genetic information and enables pathogen identification with up to >99% accuracy and antibiotic resistance detection with up to more than 98%.

4) ARES Platform - Proprietary digital health platform combines NGS-based Universal Pathogenome Assay (ARESupa) with cloud based decision support & reporting system (AREScds) that is sustainably keeping pace with rapidly evolving AMR based on an Artificial Intelligence powered in-vitro diagnostics (IVD) Reference Database (ARESdb).

5) ARESupa - Universal Pathogenome Assay (UPA) for any patient sample.

6) AREScds - Secure & HIPAA compliant cloud-based Clinical Decision Support system (CDS) linking AMR markers to treatment response.

7) Ares Gen's proprietary digital AI powered DNA testing.

In short, Ares Genetics is worth a king's ransom.

OpGen’s subsidiary Ares Genetics provides update on collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
https://finance.yahoo.com/news/opgen-subsidiary-ares-genetics-provides-113000156.html
$NVS $MRK $QGEN